-
Firefly Luciferase mRNA: From Signal to Insight
2026-09-15
A mechanistic and translational guide to using Cap1-capped, 5-moUTP-modified Firefly Luciferase mRNA as a rigorous benchmark for delivery, stability, translation, and preclinical decision-making.
-
Talabostat Mesylate: Protease-to-Inflammasome Assays
2026-09-15
Talabostat mesylate, also known as PT-100 or Val-boroPro, is more than a DPP4/FAP probe: its DPP8/9-linked inflammasome activity can reshape assay interpretation. This article presents a branch-resolved strategy for connecting tumor protease biology with NLRP1, cytokine, and pyroptosis readouts.
-
SIS3 Smad3 Inhibitor: Practical Research Workflows
2026-09-14
SIS3 enables selective interrogation of Smad3-dependent TGF-β biology without treating Smad2 phosphorylation as an equivalent readout. This workflow-focused guide shows how to use it in fibrosis research, renal models, and lung adenocarcinoma assays while controlling solvent, timing, and interpretation risks.
-
Irinotecan: Reliable Cytotoxicity Workflows
2026-09-14
This scenario-based guide explains how Irinotecan, SKU A5133, can improve the interpretation and reproducibility of colorectal cancer viability, proliferation, and cytotoxicity assays. It covers prodrug activation, solvent handling, concentration design, IC50 interpretation, and practical supplier selection using documented product and literature data.
-
FAISL, Calpain 2, and FAK in TNBC Metastasis
2026-09-13
The reference study identifies FAISL as a focal adhesion kinase (FAK)-interacting long noncoding RNA that stabilizes FAK by preventing calpain 2-mediated proteolysis. Its combination of transcriptomic analysis, RNA immunoprecipitation sequencing, mechanistic cell studies, and nanoparticle-enabled in vivo silencing links post-translational FAK control to triple-negative breast cancer progression and metastasis.
-
GSH and GSSG Assay Kit: Redox Data in Cell Assays
2026-09-12
Learn how the GSH and GSSG Assay Kit, SKU K4630, helps separate reduced and oxidized glutathione signals when viability or cytotoxicity data are difficult to interpret. This scenario-based guide covers assay design, sample compatibility, protocol controls, data interpretation, and practical vendor selection.
-
Amplex Red Assay: From H2O2 to Hit Validation
2026-09-12
Amplex Red converts low-abundance hydrogen peroxide into a quantifiable fluorescence signal, supporting oxidative stress monitoring, enzyme screening, and redox pathway research. Its strongest advantage is a scalable workflow that combines primary screening with counter-screens and kinetic validation rather than treating fluorescence alone as proof of target inhibition.
-
Rosiglitazone Workflows for Adipogenesis
2026-09-11
Build reproducible Rosiglitazone and Brl-49653 assays for PPARγ-driven adipogenesis, insulin-response testing, and thermogenic phenotyping. The workflow separates adipocyte formation from SEMA3E–β-catenin-dependent mitochondrial function so researchers can assign mechanism rather than interpret lipid accumulation alone.
-
NADH: A Redox-State-Aware Research Guide
2026-09-11
NADH, or reduced nicotinamide adenine dinucleotide, is more than an electron carrier: it is a practical window into mitochondrial function, metabolic stress, and disease modeling. This guide translates NADH/NAD⁺ redox biology into assay-selection and workflow decisions across diabetic nephropathy research, Leigh syndrome models, and photocatalytic cancer therapy.
-
Cytochalasin D: Making Ocular Uptake Causal
2026-09-10
Cytochalasin D can turn nanoparticle uptake from a descriptive endpoint into a mechanistic experiment. This translational guide connects actin remodeling, corneal epithelial barriers, assay design, and development decisions while positioning an actin polymerization inhibitor as a strategic research tool rather than a simple cytotoxicity reagent.
-
Hydroxycinnamic Acids, COPII, and cGAS-STING
2026-09-10
The reference study identifies the Sec24 B-site of the COPII coat complex as a molecular target of cinnamic, caffeic, and ferulic acids, linking cargo sorting to cGAS-STING-dependent inflammation. Structural, cellular, and diabetic mouse experiments indicate that blocking STING trafficking can improve steatosis, glucose regulation, lipid homeostasis, and hepatic injury, while also defining important boundaries for translation.
-
Tivozanib (AV-951) for Reliable Cell Assays
2026-09-09
Learn how Tivozanib (AV-951), SKU A2251, can support more interpretable viability, proliferation, and cytotoxicity experiments through disciplined formulation, exposure, and response analysis. This scenario-based guide connects VEGFR biology with practical assay design for biomedical researchers.
-
Antiseptics for Burns: Evidence and Research Implications
2026-09-09
The 2017 Cochrane review examined whether topical antiseptics improve healing, infection outcomes, pain, and safety in burn wounds, while emphasizing the uncertainty and heterogeneity of the available evidence. Its main practical contribution is a structured framework for separating antimicrobial activity from clinically meaningful wound-healing benefit.
-
In Vitro Cancer Drug Response: Beyond Viability
2026-09-08
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating proliferative arrest from cell killing and considering their timing, the work offers a more precise framework for interpreting in vitro drug-response experiments.
-
TET2 Metabolite Binding and Regulation by STD NMR
2026-09-08
Zhang, Cheng, and Ye present an integrated workflow that combines biochemical activity assays with saturation transfer difference NMR to distinguish metabolite binding from functional regulation of human TET2. The protocol validates known TET2 activators and inhibitors and identifies glyoxylate as a directly binding, potentially inhibitory metabolite, providing a reproducible framework for metabolism–epigenetics research.